Skin Cancer Channel
Topics
Medications
Quicklinks
Related Channels

Generic Erivedge

The first patent for Erivedge (vismodegib) is scheduled to expire in November 2028, which is the earliest estimated date that a generic Erivedge product might be available. However, lawsuits or new patents could delay when a generic version is made.

Can I Buy Generic Erivedge?

Erivedge™ (vismodegib) is a prescription medication approved for the treatment of basal cell carcinoma, a type of skin cancer. It is used when the cancer has spread to other parts of the body, has come back after surgery, or cannot be treated with surgery or radiation.
 
Erivedge is made by Patheon, Inc., for Genentech USA, Inc. It is protected by exclusivity rights that prevent any generic Erivedge from being manufactured in the United States.
 

When Will a Generic Version Be Available?

The first patent for Erivedge is currently set to expire in November 2028. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten this exclusivity period. This includes such things as lawsuits or patents for new Erivedge uses.
 

Is Vismodegib a Generic Erivedge?

No -- vismodegib is the active ingredient in Erivedge, but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
 
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
5 Quick Tricks for Overcoming Nicotine Cravings

Erivedge Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.